BNP Paribas Financial Markets
MRNA icon

BNP Paribas Financial Markets’s Moderna MRNA Stock Holding History

BNP Paribas Financial Markets’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$307M Buy
4,377,120
+59,901
+1% +$3.1M 0.11% 158
2026
Q1 		$219M Buy
4,317,219
+164,787
+4% +$7.69M 0.11% 183
2025
Q4 		$122M Buy
4,152,432
+3,058,933
+280% +$83.1M 0.06% 338
2025
Q3 		$28.2M Sell
1,093,499
-131,636
-11% -$3.67M 0.02% 915
2025
Q2 		$33.8M Sell
1,225,135
-222,939
-15% -$5.87M 0.02% 763
2025
Q1 		$41.1M Buy
1,448,074
+210,057
+17% +$7.45M 0.02% 693
2024
Q4 		$51.5M Buy
1,238,017
+13,840
+1% +$661K 0.03% 605
2024
Q3 		$81.8M Buy
1,224,177
+486,061
+66% +$44.6M 0.06% 330
2024
Q2 		$87.7M Sell
738,116
-8,776
-1% -$1.11M 0.07% 270
2024
Q1 		$79.6M Buy
746,892
+55,237
+8% +$5.57M 0.07% 300
2023
Q4 		$68.8M Buy
691,655
+33,374
+5% +$2.81M 0.08% 275
2023
Q3 		$68M Sell
658,281
-100,668
-13% -$11.2M 0.09% 233
2023
Q2 		$92.2M Buy
758,949
+239,878
+46% +$32M 0.12% 174
2023
Q1 		$79.7M Sell
519,071
-42,395
-8% -$6.99M 0.11% 181
2022
Q4 		$101M Buy
561,466
+116,069
+26% +$19M 0.16% 145
2022
Q3 		$52.7M Sell
445,397
-29,045
-6% -$4.41M 0.08% 266
2022
Q2 		$67.8M Sell
474,442
-61,864
-12% -$8.84M 0.11% 204
2022
Q1 		$92.4M Buy
536,306
+202,554
+61% +$34.1M 0.12% 166
2021
Q4 		$84.8M Buy
333,752
+210,489
+171% +$61.5M 0.12% 180
2021
Q3 		$47.4M Sell
123,263
-114,510
-48% -$42.2M 0.07% 306
2021
Q2 		$55.9M Sell
237,773
-25,884
-10% -$4.63M 0.07% 296
2021
Q1 		$34.5M Buy
263,657
+80,791
+44% +$11.7M 0.05% 376
2020
Q4 		$19.1M Sell
182,866
-109,930
-38% -$11.1M 0.04% 512
2020
Q3 		$20.7M Buy
292,796
+154,848
+112% +$10.8M 0.03% 513
2020
Q2 		$8.86M Buy
137,948
+100,023
+264% +$5.48M 0.02% 765
2020
Q1 		$1.14M Buy
37,925
+19,532
+106% +$449K ﹤0.01% 1829
2019
Q4 		$360K Buy
18,393
+10,140
+123% +$180K ﹤0.01% 2665
2019
Q3 		$131K Buy
8,253
+7,604
+1,172% +$112K ﹤0.01% 2967
2019
Q2 		$9.5K Buy
+649
New +$13.9K ﹤0.01% 4109

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

BNP Paribas Financial Markets's MRNA Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Moderna (MRNA) stake by 1.4% in Q2 2026, buying an estimated $3.1M and bringing the position to 4,377,120 shares worth $307M. The position accounts for 0.11% of the portfolio, ranked #158.

BNP Paribas Financial Markets first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • BNP Paribas Financial Markets held 4,377,120 shares of Moderna worth $307M as of Q2 2026.
  • BNP Paribas Financial Markets bought 59,901 Moderna shares in Q2 2026, an estimated $3.1M.
  • Moderna made up 0.11% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #158 holding.
  • BNP Paribas Financial Markets first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.